

# *TSGA10* is Specifically Expressed in Astrocyte and Over-expressed in Brain Tumors

Babak Behnam<sup>1,2,3\*</sup>, Ali Chahlavi<sup>4</sup>, Jogi Pattisapu<sup>2</sup>, and Jonathan Wolfe<sup>1</sup>

1. Department of Biology, University College London (UCL), London, UK

2. Department of Microbiology and Molecular Biology, College of Medicine, University of Central Florida (UCF), Orlando, Florida, USA

3. Department of Genetics and Molecular Biology, College of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran

4. St. Vincent's Spine and Brain Institute, Jacksonville, Florida, USA

## Abstract

In this study *TSGA10* has been demonstrated as a testis-specific human gene that encodes a protein localized in sperm-tail and conserved in ciliary structure. Further investigations showed *TSGA10* signalling and expression during embryogenesis, brain development and some malignancies including brain tumors. Given the role of this protein in neuronal development and in certain tumors, it could potentially serve as a diagnostic marker and therapeutic target in brain tumors. Therefore, using immunohistochemistry, we evaluated the localization of *TSGA10* in different regions of brain, and its pattern/level of expression in tissue microarray (Cybrdi) containing human brain tumors and normal brain. In rat specimens, *TSGA10* was mainly expressed in subventricular zone, hippocampus and granular layer of cerebellum of the brain. The antibody also stained the diverse and different types of human brain cancers. The *TSGA10* was strongly over-expressed in glioblastoma and astrocytoma when compared to normal human brain. The expression of *TSGA10* was also confirmed in astrocyte derived from a human astrocytoma cell line by immunocytochemistry. This study indicates that *TSGA10* can be used as an immunohistochemical marker for human neuroglia and astrocyte cells and is over-expressed in brain tumors.

## \* Corresponding author:

Babak Behnam, M.D.,  
Ph.D., Reproductive  
Biotechnology, Avicenna  
Research Institute, ACECR,  
Tehran, Iran, P.O. Box:  
19615-1177

Tel: +98 21 22432020

Fax: +98 21 22432021

## E-mail:

b.behnam@avicenna.ac.ir

bbehnam@iums.ac.ir

Received: 8 Nov 2009

Accepted: 2 Dec 2009

*Avicenna J Med Biotech* 2009; 1(3): 161-166

**Keywords:** Astrocytes, Brain neoplasms, Immunohistochemistry, Neuron-glia, *TSGA10* protein

## Introduction

*TSGA10* has been described as a 82-kDa protein expressed in testis and during developmental stage of spermatogenesis and embryogenesis<sup>(1)</sup>. It has already been indicated that full-length *TSGA10* is post-translational modified, and the processed N-terminus 27-kDa mature *TSGA10* is located in the Fibrous Sheath (FS) of sperm tail<sup>(2)</sup>. However, the C-terminal 55-kDa part of *TSGA10* accumulates in the midpiece of spermatozoa,

where it co-localizes with *HIF-1a*, and expressed during brain development<sup>(3)</sup>, and in some solid and nonsolid tumors as a testis-cancer antigen.

The solid tumors include melanoma, pancreatic adenocarcinoma, hepatocellular carcinoma<sup>(4)</sup> and cutaneous lymphoma<sup>(5)</sup>, ovarian leiomyosarcoma, germ cell tumor and gastric adenocarcinoma (derived ESTs). The non-solid tumors include Acute Lymphocytic Leu-

kemia (ALL) and Acute Myeloplasic Leukemia (AML) <sup>(6,7)</sup>.

The *TSGA10* interacts directly with hypoxia inducible factor-1- $\alpha$  <sup>(3)</sup> and contributes to the ciliary structure; thus it may behave such as VHL. In this study, we have shown the over-expression of *TSGA10* in brain tumors, and our eventual goal is to determine its role in brain tumorigenesis.

## Materials and Methods

### Immunohistochemistry

To study the *TSGA10* expression and localization, immunohistochemistry was performed in paraffin embedded brain tissue sections (2  $\mu$ ) including adult rat brain and a high-density tissue microarray of human brain tumors utilizing *TSGA10* antisera. For generating anti-*TSGA10* antibodies, peptides derived from the *TSGA10* N-and C-terminal regions (aa 206-219 and 676-689, respectively) which were also highly conserved in human, rat and mouse. The peptides were synthesized and conjugated to keyhole limpet hemocyanin and used to immunize two rabbits. The resultant antisera thus contained antibodies directed against both the *TSGA10* N-and C-terminal peptides.

The tissue microarray (Cybrdi) contained largely consecutive invasive brain tumor and eight normal brain tissues samples. The specificity of the polyclonal rabbit anti-*TSGA10* antibody has previously been defined and characterized <sup>(1)</sup>. The *TSGA10* protein expression was evaluated both semiquantitatively (0, 1+, 2+, 3+, 4+, 5+ scoring) and qualitatively (specificity and nonspecific background). The most reliable results (98.2% concordance; 0.9% of background) were obtained using a 1:800 primary antibody (10  $\mu$ g/ml *TSGA10* antibody) dilution. Specimens were incubated with horse-radish peroxidase goat anti-rabbit IgG (SantaCruz), and stained with DAB kits (Vetor). Mayer's hematoxylin (Sigma) was used as a counterstain. An irrelevant rabbit IgG antibody was used as an isotype control in all cases to demonstrate that staining was specific for *TSGA10*.

### Cell culture, immunocytochemistry, and direct fluorescent staining

To study localization of *TSGA10* in astrocytes, a cell line was derived from a human astrocytoma (garde III, WHO). And the astrocyte cell line (A735) cultured in Dulbecco's Modified Eagle's Medium (DMEM, high glucose) and incubated at 37 °C, 5% CO<sub>2</sub>. The astrocytes were seeded on sterilized glass cover slips treated with poly-L-lysine (Sigma) in 6-well plates.

A day after seeding, cells were fixed with methanol in -20 °C for 10 *min* and incubated with primary *TSGA10* rabbit polyclonal antibody diluted 1:50 (v/v) in blocking solution for 1 *hr* at 37 °C and washed in PBS. After washing, they were incubated for 1 *hr* at 37 °C with the relevant secondary antibody (FITC-conjugated goat anti-rabbit IgG; Jackson Immunoresearch Laboratory, Inc., West Grove, PA) in blocking solution and washed in PBS before staining with DAPI. Cover slips were mounted on glass slides with Permount SP15-100 (Fisher Scientific, Edmonton, AB, Canada), and analyzed by fluorescence microscopy (Zeiss Vision, Mannheim, Germany).

### Western blot

Twenty  $\mu$ g of total protein was separated after extraction from cultured cells by discontinuous 10% SDS-PAGE at 100 *volts* for one *hr* using a Mini-Protean III electrophoresis apparatus (Bio-Rad, Hercules, CA). Following electrophoresis, the gel was equilibrated in transfer buffer for 15 *min* and then was transferred to nitrocellulose membrane at 30 *volts* overnight at 4°C. Post transfer, the membrane was subjected to blocking per Western Breeze Chemiluminescent immunodetection protocol (Invitrogen, Carlsbad, CA) for 30 *min* at room temperature. Western blotting was performed using a 1:500 dilution of the polyclonal antibody against *TSGA10* <sup>(1)</sup> and 1:10000 dilution of the monoclonal antibody against  $\beta$ -actin proteins for 2 *hrs* at room temperature.

After primary antibody probing, the membrane was washed four times and then incu-

bated with anti-rabbit IgG horse-raddish peroxidase conjugated secondary antibody for 1 hr at room temperature, and washed with TBS (1% Tween 20 in PBS) for three times. The *TSGA10* and  $\beta$ -actin expressions were detected by ECL enhanced chemiluminescence. Following this development, the films were scanned and the images saved in JPEG format.

### Results

It has been shown that *TSGA10* is expressed in some particular regions of normal brain. The brain regions in which *TSGA10* is mainly expressed include the granular layer of cerebellum, hippocampus and subventricular zone (Figure 1). This pattern of *TSGA10* expression in the brain suggested a possible high expression of *TSGA10* in dividing astrocyte and/or glia cells.

This study has demonstrated *TSGA10* over-expression in different pathologic types of human brain tumors with a significant difference compared to normal brain. The signals were scored via a point system by two different reviewers and final scores were an average of points in different samples by different reviewers.

Table 1. *TSGA10* protein expression in 63 human brain samples

No.	Pathologic Diagnosis	<i>TSGA10</i> expression level (Score)
8	Normal Brain	1
3	Medulloblastoma	3
12	Oligodendroglioma	3.4
3	- Grade II	5
9	- Grade III	3
7	Astrocytoma (Grade III)	3.9
9	Astrocytoma (Grade II)	4
3	Pilocytic Astrocytoma	4
21	Glioblastoma	4.2

The brain tumors include glioblastoma, astrocytoma (pilocytic, grades II and III), oligodendroglioma, and medulloblastoma with highest *TSGA10* over-expression in grade II oligodendroglioma (average 5+ in three samples) followed by glioblastoma (Table 1, Figure 2).

Sixty three samples (dots) have been provided in the tissue array slide with nine different histopathologic diagnoses including 8 normal brains (1+), 3 medulloblastoma (3+), 12 oligodendroglioma (3 grade II:5+, and 9 grade III:3+), 19 astrocytoma (9 grade II:4+ and 7 grade III:3.9+, and 3 pilocytic:4+), and 21 glioblastoma (4.2+). Medulloblastoma and oligodendroglioma (grade III) generally show




Figure 1. *TSGA10* expression in rat brain

*TSGA10* is expressed in different regions of rat brain including granular layer of cerebellum, hippocampus and Subventricular zone (SVZ). These brain zones are well known as the glia-rich regions of brain






Figure 2. *TSGA10* is expressed in human normal brain and over-expressed in human brain tumors. By immunohistochemistry and utilizing polyclonal antibody (raised in rabbit) and Cybrdi tissue microarray, *TSGA10* expression is shown in normal brain, and in different brain tumors in human. *TSGA10* expression shows a significant increase in human brain tumors compared to normal brain. “Glioblastoma” followed by “pilocytic astrocytoma” and “astrocytoma (grade II)” show the highest expression of *TSGA10* protein and “medulloblastoma” the lowest among the brain tumors. (Zeiss microscope, x40)

a lower expression of *TSGA10* protein compared to other tumors. Although *TSGA10* protein seems to be expressed more in grades II compared to grade III, this difference is minimal in astrocytoma whereas maximal in oligodendroglioma. Meanwhile, the highest expression of *TSGA10* is observed in grade II oligodendroglioma. However, glioblastoma identifies maximum *TSGA10* expression as a histopathologic entity among brain tumors (Table 1).

To investigate a possible expression of *TSGA10* in an astrocyte, a cell line which was derived from a known human astrocytoma (grade III, WHO, as a gift) selected and endogenous *TSGA10* expression was shown within the cells. Using immunostaining and IF methods, the antibody against the C-terminal of *TSGA10* could localize the protein as a single spot around the nucleus, and as several

spots within the nucleus, respectively (Figure 3). We also found a significant increase in The *TSGA10* expression in this human cell line which was derived from astrocytoma, utilizing protein analysis. Western blot shows a 82 *kDa* *TSGA10* band which was more intense in above-mentioned cell line (astrocyte derived from grade III astrocytoma) than the astrocyte cell line (A735), as verified by scanning densitometry normalized to  $\beta$ -actin (Figure 4).

### Discussion

It has already been shown that *TSGA10* protein has a post-translational modification, resulting in an N-terminus 27-*kDa* and a C-terminus 55-*kDa* components<sup>(1)</sup>. Although the C-terminus *TSGA10* may be associated with an organelle such as centrosome which is consistent with its role in cell division and




Figure 3. *TSGA10* localization in astrocyte  
In immunocytochemistry, *TSGA10* antibody could detect the protein expression and localize the C-terminus (top panel) of the *TSGA10* protein as a single perinuclear spot in the culture of astrocyte which is derived from human astrocytoma (WHO, grade III). However, the N-terminus of the protein (bottom panel) is expressed within the nucleus as several spots. DAPI used for the nuclei staining and FITC-conjugated (green) secondary antibody was used in IF

proliferation however a further study in tumor biology is necessary to confirm a precise and specific function of each component.

In this study, we have demonstrated an over-expression of *TSGA10* in brain tumors with a significant difference between normal brain and malignant cells. This is consistent with the previously reported over-expression in some other tumors (4-6; BLAST/NCBI ESTs). The *TSGA10* (C-terminus) also interacts with *HIF-1-alpha* <sup>(3)</sup> and contributes to ciliary-centrosomal structure <sup>(1)</sup>. The results of this study along with prior molecular findings on the *TSGA10*, may address a crucial role in regulating brain tumorigenesis, apoptosis and hypoxia pathways. These findings on the *TSGA10* molecular behavior and expression

also remind a similar function to VHL tumor suppressor protein.

#### Acknowledgement

Authors would like to thank Prof. Sue Povey (UCL, London, UK) for providing the cell line astrocyte which was derived from a known human astrocytoma (grade III, WHO).

#### References

1. Behnam B, Modarressi MH, Conti V, Taylor KE, Puliti A, Wolfe J. Expression of Tsga10 sperm tail protein in embryogenesis and neural development: from cilium to cell division. *Biochem Biophys Res Commun* 2006;344(4):1102-1110.
2. Modarressi MH, Behnam B, Cheng M, Taylor KE, Wolfe J, van der Hoorn FA. Tsga10 encodes a 65-kilodalton protein that is processed to the 27-kilodalton fibrous sheath protein. *Biol Reprod* 2004;70(3):608-615.
3. Hagele S, Behnam B, Borter E, Wolfe J, Paasch U, Lukashev D, et al. TSGA10 prevents nuclear localization of the hypoxia inducible factor (HIF)-1 alpha. *FEBS Lett* 2006;580(15):3731-3738.
4. Tanaka R, Ono T, Sato S, Nakada T, Koizumi F, Hasegawa K, et al. 2004. Over-expression of the testis-specific gene TSGA10 in cancers and its immunogenicity. *Microbiol Immunol* 2004;48(4): 339-345.
5. Theinert SM, Pronest MM, Peris K, Sterry W, Walden P. Identification of the testis-specific protein 10 (TSGA10) as serologically defined tumour




Figure 4. *TSGA10* protein expression in astrocytes  
Western blots for *TSGA10* expression in astrocytes derived from a grade III astrocytoma (left panel) and an astrocyte cell line (735), in which its expression normalized to  $\beta$ -actin. *TSGA10* protein levels in grade III astrocytoma is significantly increased compared to the astrocyte cell line (735).

- associated antigen in primary cutaneous T-cell lymphoma. *Br J Dermatol* 2005;153(3):639-641.
6. Mobasheri MB, Modarressi MH, Shabani M, Asgarian H, Sharifian RA, Vossough P, et al. Expression of the testis-specific gene, TSGA10, in Iranian patients with acute lymphoblastic leukemia (ALL). *Leuk Res* 2006;30(7):883-889.
  7. Mobasheri MB, Jahanzad I, Mohagheghi MA, Aarabi M, Farzan S, Modarressi MH. Expression of two testis-specific genes, TSGA10 and SYCP3, in different cancers regarding to their pathological features. *Cancer Detect Prev* 2007;31(4):296-302.